This is a preprint.

It has not yet been peer reviewed by a journal.

The National Library of Medicine is running a pilot to include preprints that result from research funded by NIH in PMC and PubMed.

[Preprint]. 2024 Aug 9:2024.08.08.24311713.

doi: 10.1101/2024.08.08.24311713.

Adenomas from individuals with pathogenic biallelic variants in the MUTYH and NTHL1 genes demonstrate base excision repair tumour mutational signature profiles similar to colorectal cancers, expanding potential diagnostic and variant classification applications

Romy Walker^{1

2}, Jihoon E Joo^{1

2}, Khalid Mahmood^{1

2

3}, Mark Clendenning^{1

2}, Julia Como^{1

2}, Susan G Preston^{1

2}, Sharelle Joseland^{1

2}, Bernard J Pope^{1

3}, Ana B D Medeiros⁴, Brenely V Murillo⁵, Nicholas Pachter^{5

6

7}, Kevin Sweet⁸, Allan D Spigelman^{9

10

11}, Alexandra Groves⁹, Margaret Gleeson⁹, Krzysztof Bernatowicz¹², Nicola Poplawski^{12

13}, Lesley Andrews^{14

15}, Emma Healey^{16

17}, Steven Gallinger¹⁸, Robert C Grant¹⁹, Aung K Win^{2

20}, John L Hopper²⁰, Mark A Jenkins^{2

20}, Giovana T Torrezan^{4

21}, Christophe Rosty^{1

2

22

23}, Finlay A Macrae^{24

25

26}, Ingrid M Winship^{24

25}, Daniel D Buchanan^{1

2

24}, Peter Georgeson^{1

2}

Affiliations

¹ Colorectal Oncogenomics Group, Department of Clinical Pathology, The University of Melbourne, Parkville, VIC, 3010, Australia.
² University of Melbourne Centre for Cancer Research, Victorian Comprehensive Cancer Centre, Parkville, VIC, 3010, Australia.
³ Melbourne Bioinformatics, The University of Melbourne, Melbourne, VIC, 3053, Australia.
⁴ Clinical and Functional Genomics Group, International Research Centre/CIPE, A.C. Camargo Cancer Centre, Sao Paulo, 01508-010, Brazil.
⁵ Genetic Services of Western Australia, King Edward Memorial Hospital, Perth, WA, 6008, Australia.
⁶ Medical School, University of Western Australia, Perth, WA, 6009, Australia.
⁷ School of Medicine, Curtin University, Perth, WA, 6845, Australia.
⁸ Division of Human Genetics, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, 43210, USA.
⁹ Hunter Family Cancer Service, Newcastle, NSW, 2298, Australia.
¹⁰ St Vincent's Cancer Genetics Unit, Sydney, NSW, 2290, Australia.
¹¹ Surgical Professorial Unit, UNSW Clinical School of Clinical Medicine, Sydney, NSW, 2052, Australia.
¹² Adult Genetics Unit, Royal Adelaide Hospital, Adelaide, SA 5000, Australia.
¹³ Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia.
¹⁴ Hereditary Cancer Centre, Prince of Wales Hospital, Randwick, New South Wales, Australia.
¹⁵ School of Medicine and Public Health, University of Newcastle, Callaghan, New South Wales, Australia.
¹⁶ Prince of Wales Clinical School, Faculty of Medicine, University of New South Wales, Randwick, New South Wales 2031 Australia.
¹⁷ Illawarra Cancer Care Centre, Wollongong Hospital, Wollongong, New South Wales 2500 Australia.
¹⁸ Lunenfeld Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada.
¹⁹ Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
²⁰ Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, VIC, 3053, Australia.
²¹ National Institute of Science and Technology in Oncogenomics and Therapeutic Innovation, Sao Paulo 01508-010, Brazil.
²² Envoi Specialist Pathologists, Brisbane, QLD, 4059, Australia.
²³ University of Queensland, Brisbane, QLD, 4072, Australia.
²⁴ Genomic Medicine and Family Cancer Clinic, Royal Melbourne Hospital, Parkville, VIC, 3000, Australia.
²⁵ Department of Medicine, The University of Melbourne, Parkville, VIC, 3000, Australia.
²⁶ Colorectal Medicine and Genetics, The Royal Melbourne Hospital, Parkville, VIC, 3000, Australia.

PMID: 39148833
PMCID: PMC11326331
DOI: 10.1101/2024.08.08.24311713

Adenomas from individuals with pathogenic biallelic variants in the MUTYH and NTHL1 genes demonstrate base excision repair tumour mutational signature profiles similar to colorectal cancers, expanding potential diagnostic and variant classification applications

Romy Walker et al. medRxiv. 2024.

[Preprint]. 2024 Aug 9:2024.08.08.24311713.

doi: 10.1101/2024.08.08.24311713.

Authors

Affiliations

¹ Colorectal Oncogenomics Group, Department of Clinical Pathology, The University of Melbourne, Parkville, VIC, 3010, Australia.
² University of Melbourne Centre for Cancer Research, Victorian Comprehensive Cancer Centre, Parkville, VIC, 3010, Australia.
³ Melbourne Bioinformatics, The University of Melbourne, Melbourne, VIC, 3053, Australia.
⁴ Clinical and Functional Genomics Group, International Research Centre/CIPE, A.C. Camargo Cancer Centre, Sao Paulo, 01508-010, Brazil.
⁵ Genetic Services of Western Australia, King Edward Memorial Hospital, Perth, WA, 6008, Australia.
⁶ Medical School, University of Western Australia, Perth, WA, 6009, Australia.
⁷ School of Medicine, Curtin University, Perth, WA, 6845, Australia.
⁸ Division of Human Genetics, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, 43210, USA.
⁹ Hunter Family Cancer Service, Newcastle, NSW, 2298, Australia.
¹⁰ St Vincent's Cancer Genetics Unit, Sydney, NSW, 2290, Australia.
¹¹ Surgical Professorial Unit, UNSW Clinical School of Clinical Medicine, Sydney, NSW, 2052, Australia.
¹² Adult Genetics Unit, Royal Adelaide Hospital, Adelaide, SA 5000, Australia.
¹³ Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia.
¹⁴ Hereditary Cancer Centre, Prince of Wales Hospital, Randwick, New South Wales, Australia.
¹⁵ School of Medicine and Public Health, University of Newcastle, Callaghan, New South Wales, Australia.
¹⁶ Prince of Wales Clinical School, Faculty of Medicine, University of New South Wales, Randwick, New South Wales 2031 Australia.
¹⁷ Illawarra Cancer Care Centre, Wollongong Hospital, Wollongong, New South Wales 2500 Australia.
¹⁸ Lunenfeld Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada.
¹⁹ Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
²⁰ Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, VIC, 3053, Australia.
²¹ National Institute of Science and Technology in Oncogenomics and Therapeutic Innovation, Sao Paulo 01508-010, Brazil.
²² Envoi Specialist Pathologists, Brisbane, QLD, 4059, Australia.
²³ University of Queensland, Brisbane, QLD, 4072, Australia.
²⁴ Genomic Medicine and Family Cancer Clinic, Royal Melbourne Hospital, Parkville, VIC, 3000, Australia.
²⁵ Department of Medicine, The University of Melbourne, Parkville, VIC, 3000, Australia.
²⁶ Colorectal Medicine and Genetics, The Royal Melbourne Hospital, Parkville, VIC, 3000, Australia.

PMID: 39148833
PMCID: PMC11326331
DOI: 10.1101/2024.08.08.24311713

Update in

Adenomas from individuals with pathogenic biallelic variants in the MUTYH and NTHL1 genes demonstrate base excision repair tumour mutational signature profiles similar to colorectal cancers, expanding potential diagnostic and variant classification applications.
Walker R, Joo JE, Mahmood K, Clendenning M, Como J, Preston SG, Joseland S, Pope BJ, Medeiros ABD, Murillo BV, Pachter N, Sweet K, Spigelman AD, Groves A, Gleeson M, Bernatowicz K, Poplawski N, Andrews L, Healey E, Gallinger S, Grant RC, Win AK, Hopper JL, Jenkins MA, Torrezan GT, Rosty C, Macrae FA, Winship IM, Buchanan DD, Georgeson P. Walker R, et al. Transl Oncol. 2025 Feb;52:102266. doi: 10.1016/j.tranon.2024.102266. Epub 2025 Jan 9. Transl Oncol. 2025. PMID: 39793275 Free PMC article.

Abstract

Background: Colorectal cancers (CRCs) from people with biallelic germline likely pathogenic/pathogenic variants in MUTYH or NTHL1 exhibit specific single base substitution (SBS) mutational signatures, namely combined SBS18 and SBS36 (SBS18+SBS36), and SBS30, respectively. The aim was to determine if adenomas from biallelic cases demonstrated these mutational signatures at diagnostic levels.

Methods: Whole-exome sequencing of FFPE tissue and matched blood-derived DNA was performed on 9 adenomas and 15 CRCs from 13 biallelic MUTYH cases, on 7 adenomas and 2 CRCs from 5 biallelic NTHL1 cases and on 27 adenomas and 26 CRCs from 46 non-hereditary (sporadic) participants. All samples were assessed for COSMIC v3.2 SBS mutational signatures.

Results: In biallelic MUTYH cases, SBS18+SBS36 signature proportions in adenomas (mean±standard deviation, 65.6%±29.6%) were not significantly different to those observed in CRCs (76.2%±20.5%, p-value=0.37), but were significantly higher compared with non-hereditary adenomas (7.6%±7.0%, p-value=3.4×10^-4). Similarly, in biallelic NTHL1 cases, SBS30 signature proportions in adenomas (74.5%±9.4%) were similar to those in CRCs (78.8%±2.4%) but significantly higher compared with non-hereditary adenomas (2.8%±3.6%, p-value=5.1×10^-7). Additionally, a compound heterozygote with the c.1187G>A p.(Gly396Asp) pathogenic variant and the c.533G>C p.(Gly178Ala) variant of unknown significance (VUS) in MUTYH demonstrated high levels of SBS18+SBS36 in four adenomas and one CRC, providing evidence for reclassification of the VUS to pathogenic.

Conclusions: SBS18+SBS36 and SBS30 were enriched in adenomas at comparable proportions observed in CRCs from biallelic MUTYH and biallelic NTHL1 cases, respectively. Therefore, testing adenomas may improve the identification of biallelic cases and facilitate variant classification, ultimately enabling opportunities for CRC prevention.

Keywords: Colorectal cancer; MUTYH; NTHL1; SBS18; SBS30; SBS36; adenoma; hereditary cancer predisposition; mutational signature; variant of uncertain clinical significance.

PubMed Disclaimer

Conflict of interest statement

Robert C. Grant received a scholarship from Pfizer and provided consulting or advisory roles for Astrazeneca, Tempus, Eisai, Incyte, Knight Therapeutics, Guardant Health, and Ipsen. All other authors have no relevant financial or non-financial interests to disclose.

Figures

**Figure 1:**
Mutational signatures observed across the cohort. Abbreviations: MMR, DNA mismatch repair; SBS, single base substitution; CRC,colorectal cancer.

**Figure 2:**
Boxplots of whole-exome sequencing derived genomic features for A) SBS18+SBS36 proportions in *MUTYH* cases and non-hereditary groups and B) SBS30 proportions in *NTHL1* cases and non-hereditary groups. Abbreviations: MMR, DNA mismatch repair; SBS, single base substitution; CRC,colorectal cancer; VUS, variant of uncertain significance; LP, likely pathogenic.

**Figure 3.**
Line plot displaying the comparison of SBS18+SBS36 signature proportions for adenomas and colorectal cancers related to each biallelic *MUTYH* case and for the participant with a pathogenic and variant of uncertain significance in *MUTYH* (Pat_763). Abbreviations: SBS, single base substitution; CRC, colorectal cancer; VUS, variant of uncertain significance; LP, likely pathogenic; ID, identification; Pat, patient ID; Rel, relative ID.

See this image and copyright information in PMC

References

1. Al-Tassan N, Chmiel NH, Maynard J, Fleming N, Livingston AL, Williams GT, et al. Inherited variants of MYH associated with somatic G:C→T:A mutations in colorectal tumors. Nat Genet 2002;30:227–32. 10.1038/ng828. - DOI - PubMed
1. Weren RDA, Ligtenberg MJL, Kets CM, de Voer RM, Verwiel ETP, Spruijt L, et al. A germline homozygous mutation in the base-excision repair gene NTHL1 causes adenomatous polyposis and colorectal cancer. Nat Genet 2015;47:668–71. 10.1038/ng.3287. - DOI - PubMed
1. Win AK, Reece JC, Dowty JG, Buchanan DD, Clendenning M, Rosty C, et al. Risk of extracolonic cancers for people with biallelic and monoallelic mutations in MUTYH. Int J Cancer 2016;139:1557–63. 10.1002/ijc.30197. - DOI - PMC - PubMed
1. Grolleman JE, Díaz-Gay M, Franch-Expósito S, Castellví-Bel S, de Voer RM. Somatic mutational signatures in polyposis and colorectal cancer. Mol Aspects Med 2019;69:62–72. 10.1016/j.mam.2019.05.002. - DOI - PubMed
1. Georgeson P, Pope BJ, Rosty C, Clendenning M, Mahmood K, Joo JE, et al. Evaluating the utility of tumour mutational signatures for identifying hereditary colorectal cancer and polyposis syndrome carriers. Gut 2021;70:2138–49. 10.1136/gutjnl-2019-320462. - DOI - PMC - PubMed

Publication types

Actions

Grants and funding

U01 CA167551/CA/NCI NIH HHS/United States

LinkOut - more resources

Full Text Sources
- Cold Spring Harbor Laboratory
- PubMed Central
Research Materials
- NCI CPTC Antibody Characterization Program

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

This is a preprint.

Adenomas from individuals with pathogenic biallelic variants in the MUTYH and NTHL1 genes demonstrate base excision repair tumour mutational signature profiles similar to colorectal cancers, expanding potential diagnostic and variant classification applications

Affiliations

Adenomas from individuals with pathogenic biallelic variants in the MUTYH and NTHL1 genes demonstrate base excision repair tumour mutational signature profiles similar to colorectal cancers, expanding potential diagnostic and variant classification applications

Authors

Affiliations

Update in

Abstract

Conflict of interest statement

Figures

Similar articles

References

Publication types

Grants and funding

LinkOut - more resources

Full Text Sources

Research Materials

This is a preprint.

Update in

Abstract

Conflict of interest statement

Figures

Similar articles

References

Publication types

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Research Materials